Valeant Profit Rises Amidst Allergan Push

Jul 31 2014 | 11:41am ET

Valeant Pharmaceuticals International turned its second-quarter results announcement into another pitch for its $54 billion offer for rival Allergan Inc.

The Canadian company, which is working with Pershing Square Capital Management on its bid for Allergan, pointed to growth in almost all of its business lines as it announced higher profits and sales. And it said that it remains “focused on completing the Allergan transaction,” in spite of that company’s opposition to it.

Valeant has launched a hostile tender offer for Allergan, while Pershing Square seeks to oust the company’s board. Valeant said it planned to integrate Allergan in much the same way it merged with Bausch & Lomb.

That’s not likely to offer much comfort to Allergan, which has blasted Valeant as a serial acquirer with an unsustainable business strategy.


In Depth

An Interview With Harvest Volatility Management's Rick Selvala

Mar 23 2017 | 5:39pm ET

Several years of extremely low interest rates have pushed some investors into equities...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

SEI: Private Debt Coming Into Its Own

Mar 8 2017 | 9:24pm ET

The explosive growth of private debt over the past few years has caused the lines...